TRVI
NASDAQ · Pharmaceuticals
Trevi Therapeutics Inc
$11.44
+0.80 (+7.52%)
Financial Highlights (FY 2025)
Revenue
772.80M
Net Income
98.54M
Gross Margin
61.6%
Profit Margin
12.8%
Rev Growth
+0.7%
D/E Ratio
0.64
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 61.6% | 61.6% | 61.6% |
| Operating Margin | 22.4% | 22.6% | 18.4% |
| Profit Margin | 12.8% | 15.2% | 13.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 772.80M | 683.27M | 746.33M |
| Gross Profit | 476.41M | 421.22M | 460.09M |
| Operating Income | 172.98M | 154.37M | 137.33M |
| Net Income | 98.54M | 104.02M | 99.75M |
| Gross Margin | 61.6% | 61.6% | 61.6% |
| Operating Margin | 22.4% | 22.6% | 18.4% |
| Profit Margin | 12.8% | 15.2% | 13.4% |
| Rev Growth | +0.7% | +7.7% | +15.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 717.28M | 699.31M | 738.29M |
| Total Equity | 1.12B | 1.05B | 1.05B |
| D/E Ratio | 0.64 | 0.66 | 0.70 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 196.14M | 177.32M | 185.79M |
| Free Cash Flow | 50.24M | 55.58M | 60.41M |